Coherus BioSciences (NASDAQ:CHRS) Price Target Cut to $12.00 by Analysts at Maxim Group

Coherus BioSciences (NASDAQ:CHRS – Get Rating) had its price objective trimmed by Maxim Group from $15.00 to $12.00 in a report issued on Friday, The Fly reports. A number of other analysts have also recently issued reports on the company. StockNews.com began coverage on Coherus BioSciences in a report on Thursday, March 16th. They set […]

Related Keywords

Coherus Biosciences ,Dennism Lanfear ,Doug Farrar ,Steve Glover ,Alan Herman ,Eagle Bay Advisors ,Coherus Biosciences Inc ,Barclays ,Verition Fund Management ,Maxim Group ,Coherus Biosciences Company Profile ,Hermes Inc ,Get Rating ,Moderate Buy ,Biosciences Trading Down ,Financial Advisors ,Bay Advisors ,Forest Capital Management ,Redwood City ,Coherus Biosciences Daily ,Nasdaq Chrs ,Chrs ,Medical ,Lower Price Target ,